Market Currents
Savient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates....
-
Wednesday, May 9, 2012, 1:10 PM ETSavient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates. Total revenue actually jumped nearly 170% Y/Y, but bottom line margins were hit as expenses increased sharply. Much of the increase in expenses had to do with the commercialization and marketing of its new gout drug Krystexxa.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
